Sites will be able to easily access systems across multiple sponsors and studies for increased efficiency and speed
BARCELONA, Spain, Sept. 13, 2023 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced Veeva Study Portal, a free cloud application to simplify research site access to sponsor technologies. Study Portal will make it easy for clinical researchers to create and share study profiles containing links to all the relevant sponsor technology systems used for a clinical trial. Users will be able to securely store their individual usernames and passwords with the study profile rather than managing multiple links, usernames, and passwords on sticky notes or spreadsheets. Study Portal will work with all sponsor technology systems.
In addition to Study Portal, Veeva announced VeevaID to provide single sign-on for clinical researchers across all sponsor systems, such as Veeva Vault EDC, Veeva Vault Study Training, and Veeva RTSM. When sponsors use Veeva technology and enable VeevaID, the access links in Study Portal will take the user directly to the relevant study screen via single sign-on with no additional username and password required.
"Research sites are focused on patient care, so alleviating the administrative burden of managing large lists of credentials across studies and partners is not a luxury but a necessity," said Dr. Viviënne van de Walle, principal investigator, medical director, PT&R. "Veeva Study Portal is a significant step forward to simplify the technology experience for sites. By providing this at no cost to sites, Veeva is delivering on the vision of offering solutions that are centric to the needs of sites."
VeevaID will also be open to Veeva partners who join the VeevaID partner program, adhere to security standards, and have integrated the VeevaID technology. The program will allow third-party vendors to authenticate using VeevaID for direct system entry through the Study Portal.
Veeva Study Portal and VeevaID are planned for availability in December 2023. Veeva provides free technology solutions to research sites as part of its mission as a Public Benefit Corporation (PBC). Learn more about Veeva Study Portal at studyportal.veeva.com.
Additional Information For more on Veeva's site solutions, visit sites.veeva.com
Connect with Veeva on LinkedIn: linkedin.com/company/veeva-systems
About Veeva Systems
Veeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,000 customers, ranging from the world's largest biopharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com/eu.
Veeva Forward-looking Statements
This release contains forward-looking statements regarding Veeva's products and services and the expected results or benefits from use of our products and services, including certain of our new solutions and applications that are still under development or not generally available. These statements are based on our current expectations. Actual results, availability, and any future events relating to these products and services could differ materially from those anticipated or provided in this release and we have no obligation to update such statements. There are numerous risks that have the potential to negatively impact our results, including the risks and uncertainties disclosed in our filing on Form 10-Q for the period ended July 31, 2023, which you can find here (a summary of risks which may impact our business can be found on pages 38 and 39), and in our subsequent SEC filings, which you can access at sec.gov.
Contact: | |
Jeremy Whittaker | Deivis Mercado |
Logo - https://mma.prnewswire.com/media/1488285/Veeva_Systems_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/veeva-introduces-study-portal-and-veevaid-to-streamline-research-site-trial-execution-301925368.html
